{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026397","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.052869+00:00","generated_at":"2026-05-31T09:40:31.638432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21","bullets":["Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.","FDA advisory committee voted arimoclomol effective for NPC; PDUFA target action date Sept 21, 2024.","Pro-forma cash $113.8M after $64.5M net from August public offering; cash runway into Q1 2027.","OLPRUVA added 9 new patient enrollments in Q2; reimbursement coverage expanded to 75% of covered lives.","Refinanced debt with $100M credit facility from Perceptive Advisors and HCR; initial draw $60M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026397","json":"https://secwatch.observer/filing/0001437749-24-026397.json","markdown":"https://secwatch.observer/filing/0001437749-24-026397.md","text":"https://secwatch.observer/filing/0001437749-24-026397.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/0001437749-24-026397-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924026397/zvra20240520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:40:31.638432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}